Search: id:"swepub:oai:DiVA.org:su-80421" >
Low PiB PET retenti...
Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers
-
- Scholl, Michael (author)
- Karolinska Institutet
-
- Wall, Anders (author)
- Uppsala universitet,Enheten för nuklearmedicin och PET
-
- Thordardottir, Steinunn (author)
- Karolinska Institutet
-
show more...
-
- Ferreira, Daniel (author)
- Karolinska Institutet
-
- Bogdanovic, Nenad (author)
- Karolinska Institutet
-
- Långström, Bengt (author)
- Uppsala universitet,Fysikalisk-organisk kemi
-
- Almkvist, Ove (author)
- Karolinska Institutet,Stockholms universitet,Psykologiska institutionen
-
- Graff, Caroline (author)
- Karolinska Institutet
-
- Nordberg, Agneta (author)
- Karolinska Institutet
-
show less...
-
(creator_code:org_t)
- 2012
- 2012
- English.
-
In: Neurology. - 0028-3878 .- 1526-632X. ; 79:3, s. 229-236
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Objective: To investigate the particular pathology of the Arctic APP (APParc) early-onset familial Alzheimer disease (eoFAD) mutation for the first time in vivo with PET in comparison with other eoFAD mutations and sporadic Alzheimer disease (sAD). Methods: We examined 2 APParc mutation carriers together with 5 noncarrier siblings cross-sectionally with C-11-labeled Pittsburgh compound B (PiB) and F-18-fluorodeoxyglucose (FDG) PET, as well as MRI, CSF biomarkers, and neuropsychological tests. Likewise, we examined 7 patients with sAD, 1 carrier of a presenilin 1 (PSEN1) mutation, 1 carrier of the Swedish APP (APPswe) mutation, and 7 healthy controls (HCs). Results: Cortical PiB retention was very low in the APParc mutation carriers while cerebral glucose metabolism and CSF levels of A beta(1-42), total and phosphorylated tau were clearly pathologic. This was in contrast to the PSEN1 and APPswe mutation carriers revealing high PiB retention in the cortex and the striatum in combination with abnormal glucose metabolism and CSF biomarkers, and the patients with sAD who showed typically high cortical PiB retention and pathologic CSF levels as well as decreased glucose metabolism when compared with HCs. Conclusions: The lack of fibrillar beta-amyloid (A beta) as visualized by PiB PET in APParc mutation carriers suggests, given the reduced glucose metabolism and levels of A beta(1-42) in CSF, that other forms of A beta such as oligomers and protofibrils are important for the pathologic processes leading to clinical Alzheimer disease. Neurology(R) 2012;79:229-236
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
Neurology
(Search for host publication in LIBRIS)
To the university's database